靶向治疗启动对银屑病关节炎相关治疗使用及医疗消费的影响:基于法国医疗保险数据库SNDS的9793例患者队列研究
基于法国国家医疗保险数据库SNDS的全国性队列研究纳入9793例新启动靶向治疗的成人银屑病关节炎患者,比较启动靶向治疗前后相关治疗使用、住院和病假比例的变化。结果显示启动靶向治疗后NSAIDs、阿片类镇痛药、泼尼松、甲氨蝶呤及情绪障碍治疗使用比例均显著降低,住院和病假亦减少;TNFi对NSAIDs和泼尼松的节省效应略大于IL17i和IL12/23i,但甲氨蝶呤停药几率以TNFi较低。
要点
- 启动靶向治疗后NSAIDs使用比例降低15%、阿片类镇痛药降低9%、泼尼松降低9%、甲氨蝶呤降低15%、情绪障碍治疗降低2%。
- 启动靶向治疗后住院比例降低12%、病假降低4%。
- TNFi对NSAIDs和泼尼松的节省效应略大于IL17i和IL12/23i,但甲氨蝶呤停药几率以TNFi较低。
核心结论
- 银屑病关节炎启动靶向治疗可减少相关伴随治疗的使用及医疗消费,TNFi效应略大于IL17i和IL12/23i,甲氨蝶呤停药除外。
研究设计与样本
- 基于法国医疗保险数据库SNDS的全国性队列研究,纳入2015-2021年间新启动靶向治疗≥9个月的成人银屑病关节炎患者9793例。
主要发现
- 启动靶向治疗后,NSAIDs使用者比例降低15%、阿片类镇痛药降低9%、泼尼松降低9%、甲氨蝶呤降低15%、情绪障碍治疗降低2%。
- 启动靶向治疗后住院比例降低12%、病假降低4%。
- TNFi对NSAIDs和泼尼松的节省效应大于IL17i(ORa=1.04,95%CI 1.01至1.07;ORa=1.04,95%CI 1.02至1.06)和IL12/23i(ORa=1.07,95%CI 1.04至1.10;ORa=1.06,95%CI 1.04至1.09)。
- 甲氨蝶呤停药几率TNFi低于IL17i(ORa=0.96,95%CI 0.94至0.98)和IL12/23i(ORa=0.94,95%CI 0.92至0.97)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess the potential impact of targeted therapies for psoriatic arthritis (PsA) on symptomatic treatments (non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioid analgesics), methotrexate and mood disorder treatments and on hospitalisation and sick leave. METHODS: Using the French health insurance database, this nationwide cohort study included adults with PsA who were new users (not in the year before the index date) of targeted therapies for ≥9 months during 2015-2021. Main endpoints were difference in proportion of users of associated treatments, hospitalisations and sick leaves between 3 and 9 months after and 6 months before targeted therapy initiation. Logistic regression models adjusted for sex, age, psoriasis, inflammatory bowel disease and Charlson Comorbidity Index compared the impact of biologics initiation (tumour necrosis factor inhibitor (TNFi)/interleukin 17 inhibitor (IL17i)/IL12/23i) on associated treatment discontinuation. RESULTS: Among 9793 patients initiating targeted therapy for PsA (mean age: 51±13 years, 47% men), 62% initiated TNFi, 14% IL17i, 10% IL12/23i, 1% Janus kinase inhibitor, 12% phosphodiesterase-4 inhibitor. After treatment initiation, the proportion of treatment users was significantly reduced for NSAIDs (-15%), opioid analgesics (-9%), prednisone (-9%), methotrexate (-15%) and mood disorder treatments (-2%), along with decreased hospitalisations (-12%) and sick leaves (-4%). TNFi had a greater sparing effect on NSAIDs and prednisone use than IL17i (ORa=1.04, 95% CI=1.01 to 1.07; 1.04, 1.02 to 1.06) and IL12/23i (1.07, 1.04 to 1.10; 1.06, 1.04 to 1.09). Odds of methotrexate discontinuation was reduced with TNFi versus IL17i (0.96, 0.94 to 0.98) and IL12/23i (0.94, 0.92 to 0.97). CONCLUSIONS: Targeted therapy initiation for PsA reduced the use of associated treatment and healthcare, with TNFi having a slightly greater effect than IL17i and IL12/23i, except for methotrexate discontinuation.
引用
- Pina Vegas L, Iggui S, Sbidian E, et al. Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS). RMD Open. 2024. PMID: 39117446. doi:10.1136/rmdopen-2024-004631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。